

Roche opens Innovation Centre in US to drive advancements in Cardiovascular, Renal and Metabolic diseases

September 21, 2026 | News

This is part of Roche and Genentech's \$50 billion investment in US manufacturing and R&D



Swiss pharma firm Roche has announced the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech's US research presence in one of the world's leading life sciences communities.

Located at Harvard's Enterprise Research Campus in Allston, the Roche Genentech Innovation Center Boston will serve as Roche's Cardiovascular, Renal and Metabolism (CVRM) hub, establishing a significant end-to-end R&D presence in CVRM.

With the new centre, Roche and Genentech are expanding their footprint within the Greater Boston innovation ecosystem, leveraging local talent and anchoring an entrepreneurial hub at Harvard's Enterprise Research Campus. It brings together scientists from across discovery research, clinical development, artificial intelligence and data science disciplines, and creates an end-to-end research environment spanning early-stage discovery through late-stage clinical development.

The Innovation Center is part of Roche and Genentech's investment commitment in US manufacturing and R&D and builds on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. Together, these investments expand an end-to-end US footprint spanning research, development and manufacturing and reflect the companies' long-term commitment to American scientific innovation. Roche and Genentech have around 25,000 employees in the United States, with 15 R&D centres and 13 manufacturing sites across Pharma and Diagnostics.